Sharh maqola

The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis

Feng LiGuangzhou Medical UniversityCaichen LiDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, ChinaXiuyu CaiDepartment of General Internal Medicine, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaZhanhong XieGuangzhou Medical UniversityLiquan ZhouDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, ChinaBo ChengFirst Affiliated Hospital of Guangzhou Medical UniversityRan ZhongFirst Affiliated Hospital of Guangzhou Medical UniversityShan XiongState Key Laboratory of Respiratory DiseaseJianfu LiGuangzhou Medical UniversityZhuxing ChenState Key Laboratory of Respiratory DiseaseZiwen YuState Key Laboratory of Respiratory DiseaseJianxing HeFirst Affiliated Hospital of Guangzhou Medical UniversityWenhua LiangDepartment of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, China

2021en

ABI

Annotatsiya

Background: The responses of cancer patients to immune checkpoint inhibitors (ICIs) vary in success. CD8+ tumor infiltrating lymphocytes (TILs) play a key role in killing tumor cells. This study aims to evaluate the prognostic role of CD8+ TILs in cancer patients treated with ICIs. Methods: We systematically searched all publications from PubMed, EMBASE, and Cochrane Library until 12 Jul 2021 without any restriction of language or article types. Studies assessing high versus low CD8+ TILs in predicting efficacy and survival of various cancer patients were included. The outcomes included overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). The study protocol is prospectively registered on PROSPERO (registration number CRD42021233654). Findings: Findings: A total of 33 studies consisting of 2559 cancer patients were included. The result showed that high CD8+ TILs were significantly associated with better OS (HR, 0.52; 95% confidence interval: 0.410.67; p < 0.001), PFS (HR, 0.52; 95% confidence interval: 0.400.67; p < 0.001) and ORR (OR, 4.08; 95% confidence interval: 2.736.10; p < 0.001) in patients treated with ICIs. Subgroup analyses suggested that patients with high CD8+ TILs had a better clinical benefit, regardless of different treatments (ICI mono therapy, or combination therapy), cancer types (NSCLC, melanoma and others), and CD8+ T cells locations (intratumor, stroma, and invasive margin). The higher baseline circulating CD8+ T cells from peripheral blood did not contribute to the improved OS (HR, 0.93; 95% confidence interval: 0.671.29; p = 0.67) and PFS (HR, 0.89; 95% confidence interval: 0.601.32; p = 0.56) compared with the low baseline. Interpretation: Interpretation: Our results suggested that high intra-tumoral, stromal, or invasive marginal, but not circulating CD8+ T cells, can predict treatment outcomes in patients with ICIs therapy across different cancers, in either single-agent ICIs or combination with other therapies.

Hali tarjima qilinmagan

Identifikatorlar

DOI: 10.1016/j.eclinm.2021.101134

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba